There are an increasing amount of promising targeted therapies being investigated for multiple myeloma (MM). In this interview, Niels van de Donk, MD, PhD, from VU University Medical Centre, Amsterdam, Netherlands, speaking from the 1st European Myeloma Network (EMN) Meeting, held in Turin, Italy, discusses techniques for progressing to durable tumor-free remission. Dr van de Donk describes the pros and cons of various antibody treatments, whilst highlighting the importance of using a tumor map for improving induction, consolidation and maintenance therapy.
New strategies for durable remission in MM
